Tirzepatide Research Hub

Tirzepatide is a 39-amino-acid dual agonist of the GLP-1 and GIP receptors, with a C20 fatty diacid moiety for albumin binding (CAS 2023788-19-2, about 4813.5 Da). It is studied in research on incretin signalling, glucose handling, and adipose-tissue biology.

Semaglutide activates only the GLP-1 receptor; tirzepatide also activates the GIP receptor. In reported animal studies the dual profile produces a stronger metabolic effect than single-receptor analogs. Our comparison article covers the mechanisms side by side.

Retatrutide adds activity at the glucagon receptor to the GLP-1 and GIP activity that tirzepatide has. That third receptor is the basis of research into energy expenditure and hepatic lipid handling.

QSC supplies 5, 10, 15, 20, 30, 40, 50, 60, 80, 100 and 120 mg vials. Choose by stock concentration and how quickly you will use the solution: a 10 mg vial in 2 mL gives 5 mg/mL, and a 60 mg vial in 6 mL gives 10 mg/mL. Check the vial capacity before adding solvent.

Reconstitution is typically at 5 to 10 mg/mL in sterile water depending on protocol. The acetate counterion content is reflected on the COA, so adjust for effective peptide content if your protocol calls for it. Keep lyophilized powder at -20°C for long-term storage and refrigerate after reconstitution.

Pre-mixed research blends are available with cagrilintide (10 mg and 20 mg vials) and with retatrutide (a 1:1 blend, 30 mg of each per 60 mg vial). Each is a single reconstitution step for protocols that use both compounds.

Prices are per 10-vial pack of one size. Email us to arrange a smaller order at the same per-vial price. Orders of $1,000 or more ship free, and delivery is typically about 10 to 15 days, duties paid.

The research-grade material QSC supplies is not approved for human or veterinary use and is sold strictly for laboratory research. Nothing on this site is medical advice.